Cheng-Yu Chang
Overview
Explore the profile of Cheng-Yu Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo J, Chang C, Chang S, Wei Y, Chen C
Curr Oncol
. 2025 Jan;
32(1).
PMID: 39851952
Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This...
2.
Tsay S, Chang C, Su J, Hung S, Mu P
JBI Evid Implement
. 2024 Nov;
PMID: 39530241
Introduction: The lack of a consistent and effective assessment tool for older adults with dementia in home care in Taiwan, and the inability of home care nurses to provide pharmacological...
3.
Chang S, Wei Y, Chen C, Lai Y, Hu P, Hung J, et al.
Mol Diagn Ther
. 2024 Aug;
28(6):803-810.
PMID: 39147938
Introduction: Comprehensive next-generation sequencing (NGS) of non-small-cell lung cancer specimens can identify oncogenic driver mutations and their corresponding targeted therapies. Plasma cell-free DNA (cfDNA) genotyping is easy to perform; however,...
4.
Tsay S, Chang C, Hung S, Su J, Kuo C, Mu P
Int J Med Inform
. 2024 May;
188:105475.
PMID: 38743995
Introduction: Pain conditions are common in elderly individuals, including those with dementia. However, symptoms associated with dementia may lead to poor recognition, assessment and management of pain. In this study,...
5.
Chang C, Chang S, Wei Y, Tseng Y, Chou C, Chen Y, et al.
Am J Cancer Res
. 2024 Apr;
14(3):1243-1257.
PMID: 38590421
The immune system plays a key role in detecting and fighting cancerous tumors. T cells are a crucial component in both natural and therapeutic cancer immunoediting responses, but it is...
6.
Chen H, Kuo Y, Chen C, Chang C, Wang S, Chien Y, et al.
Oncologist
. 2024 Jan;
29(4):e498-e506.
PMID: 38227604
Objective: Reports of tuberculosis (TB) during anticancer treatment with immune checkpoint inhibitors (ICIs) are increasing. However, it is not clear whether the use of ICIs is a significant risk factor...
7.
Chang C, Wei Y, Chen C, Lai Y, Hu P, Hung J, et al.
Front Med (Lausanne)
. 2023 Nov;
10:1242260.
PMID: 37964885
Introduction: Randomized controlled trials have demonstrated a reduction in the decline of lung function and a reduced risk of acute exacerbation in patients with idiopathic pulmonary fibrosis treated with the...
8.
Lee B, Chang C
Oncol Lett
. 2023 Sep;
26(4):455.
PMID: 37720677
Capmatinib is a medication used to treat patients with non-small cell lung cancer (NSCLC) who have a specific genetic mutation known as a mesenchymal-epithelial transition exon 14 skipping mutation. Previous...
9.
Chang C, Chen C, Chang S, Chen C, Lai Y, Chang C, et al.
Front Oncol
. 2023 Jul;
13:1104098.
PMID: 37409246
Purpose: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for advanced -mutant non-small-cell lung cancer (NSCLC) patients. However, factors associated with outcomes after progression on first-line therapy...
10.
Cheng S, Wang P, Chang C, Wang H, Wang C, Chiu K
Drug Des Devel Ther
. 2023 Jan;
17:87-92.
PMID: 36698540
Background: Molnupiravir (MOL) is an oral antiviral medication that has recently been treated for COVID-19. Objectively: We perform a prospective and observational study to elucidate the efficacy and safety of...